$REG

REG Maintained by UBS -- Price Target Lowered to $77.00

UBS maintained a neutral rating on Regency Centers (REG) but lowered its price target from $85.00 to $77.00. GuruFocus values REG at $78.77, suggesting an 8.5% undervaluation. The company has a GF Score of 81/100, indicating strong performance. 8 gurus hold REG, with 5 adding positions recently. REG operates grocery-anchored shopping centers with a market cap of $13.2B.

Original reporting
Published Oct 9, 2026, 6:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 7:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$REG
Bearish
medium confidence
Mentioned
$REG
Relevance
6/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$REGBearishMed
01

Why it matters

Analyst target reduction may prompt short-term price adjustments.

02

Market read

The rating change provides fresh guidance for traders monitoring REIT sector sentiment.

03

What to watch

Strong occupancy rates and dividend yield could offset the price target reduction.

Relevance 6/10Novelty 6/10Timing: today

Background

UBS maintained a neutral rating on REG while adjusting its price target.

Company-level read

Ticker impact

$REGBearishMedium confidence
Context

UBS lowered REG's price target to $77, down from $85, indicating a more cautious outlook.

Expected impact

likely pressure as the market prices in the lower target

Evidence & confidence

Analyst downgrade without new earnings or catalyst typically leads to short-term sell pressure.

Market effects

May weigh on other REITs focused on retail properties.

Limited to US real estate market.

Low

Counterpoint

Target cut could be overcautious; the REIT's stable cash flow may support upside.

Key entities

  • Regency Centers

    US-listed REIT focusing on grocery-anchored shopping centers.

  • UBS

    Financial services firm providing the rating update.

Related articles

$EVGOMed

EVgo, Regency expand partnership with 400 new EV charging stalls

EVgo and Regency Centers are adding 400 fast-charging stalls at U.S. shopping centers, expanding their 2020 partnership. The new stations will increase Regency's EV charging footprint by over 20%, with locations in major markets. EVgo's chargers can fully charge a vehicle in 15 minutes. The companies aim to meet EV driver demand and support sustainability goals.

$JNJMed

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer

Johnson & Johnson (JNJ) reported that its RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) combination showed a 77% overall response rate in first-line treatment of advanced head and neck cancer. The study, presented at ESMO Congress 2026, demonstrated deep and durable responses, with 65% ongoing at clinical cutoff. The results support the ongoing Phase 3 OrigAMI-5 study and highlight the role of dual-targeting EGFR and MET, key drivers of tumor growth and resistance in 80-90% of HNSCC.

$AVBPMedAI 8/10

ArriVent reports phase 1 data for cancer drug ARR-217

ArriVent BioPharma (AVBP) reported initial Phase 1 results for ARR-217, showing a 44.8% objective response rate at 6 mg/kg dose in pre-treated colorectal cancer patients. The study included 123 patients with gastrointestinal malignancies. ARR-217 is being developed with Lepu Biopharma. Phase 1b dose optimization is underway, with further data expected in 2027.

$AVBPMedAI 8/10

At one dose, an experimental cancer drug had a 44.8% response rate after earlier colorectal cancer treatments.

ArriVent BioPharma (AVBP) reported Phase 1 results for ARR-217, showing a 44.8% response rate in colorectal cancer patients at a 6mg/kg dose. The drug was generally well-tolerated. ArriVent plans a Phase 1b dose optimization study, with data expected in 2027. ARR-217 is a cadherin-17-targeting antibody-drug conjugate developed with Lepu Biopharma.

$AMRNMedAI 8/10

Amarin’s icosapent ethyl shows survival benefit in cancer trial

Amarin Corporation (NASDAQ:AMRN) reported Phase 3 trial results for icosapent ethyl in colorectal cancer liver metastases. The primary endpoint of progression-free survival was not met, but the key secondary endpoint of overall survival showed a statistically significant benefit. The five-year overall survival estimate was 62.0% with icosapent ethyl versus 45.1% with placebo. The drug was found to be safe and well tolerated.